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Abstract
Background and aims: Small bowel capsule endoscopy (SBCE) allows mapping of small bowel 
inflammation in Crohn’s disease (CD). We aimed to assess the prognostic value of the severity of 
inflammatory lesions, quantified by the Lewis score (LS), in patients with isolated small bowel CD.
Methods: A retrospective study was performed in which 53 patients with isolated small bowel 
CD were submitted to SBCE at the time of diagnosis. The Lewis score was calculated and patients 
had at least 12 months of follow-up after diagnosis. As adverse events we defined disease flare 
requiring systemic corticosteroid therapy, hospitalization and/or surgery during follow-up. We 
compared the incidence of adverse events in 2 patient subgroups, i.e. those with moderate or 
severe inflammatory activity (LS ≥790) and those with mild inflammatory activity (135 ≤ LS < 790).
Results: The LS was ≥790 in 22 patients (41.5%), while 58.5% presented with LS between 135 and 
790. Patients with a higher LS were more frequently smokers (p = 0.01), males (p = 0017) and under 
immunosuppressive therapy (p = 0.004). In multivariate analysis, moderate to severe disease at 
SBCE was independently associated with corticosteroid therapy during follow-up, with a relative 
risk (RR) of 5 (p = 0.011; 95% confidence interval [CI] 1.5–17.8), and for hospitalization, with an RR 
of 13.7 (p = 0 .028; 95% CI 1.3–141.9).
Conclusion: In patients with moderate to severe inflammatory activity there were higher 
prevalences of corticosteroid therapy demand and hospitalization during follow-up. Thus, 
stratifying the degree of small bowel inflammatory activity with SBCE and LS calculation at the 
time of diagnosis provided relevant prognostic value in patients with isolated small bowel CD.
Keywords:  Crohn’s disease; small bowel capsule endoscopy; Lewis score; prognosis
1. Introduction
Crohn’s disease (CD) is a heterogeneous entity that can affect the 
entire gastrointestinal tract. In up to 60% of patients the disease 
has small bowel involvement.1–3 In patients with CD diagnosed by 
ileocolonoscopy, an investigation to determine the extent of CD in 
the small bowel is advisable.2 This evaluation can be achieved by 
cross-sectional imaging by magnetic resonance enterography (MRE), 
computed tomography enterography (CTE) or small bowel capsule 
endoscopy (SBCE).4 Although SBCE can only be used in patients 
with inflammatory phenotype (non-stricturing, non-penetrating) 
CD, with respect to mild lesions or those located in the proximal 
small bowel it has been clearly demonstrated that this method is 
more sensitive than MRE and CTE.3,5 Recent studies have shown 
an association between jejunal lesions and worse clinical outcomes;6 
 Journal of Crohn's and Colitis Advance Access published October 9, 2015
moreover, the location and particularly the severity of small bowel 
lesions in patients with CD may influence therapeutic management,7 
reinforcing the importance of SBCE in patients with CD.
Several endoscopic scores (Rutgeerts score8, the CD endoscopic 
index of severity [CDEIS]9 and the simple endoscopic score for CD 
[SES-CD]10) have been developed to assess luminal CD endoscopic 
activity. Recent guidelines4 for endoscopy in CD suggest the use of 
these scores in clinical practice since they have prognostic value.
A semi-quantitative scoring index, the Lewis score (LS),11 has 
been proposed to quantify the inflammatory activity of the small 
bowel in CD. This score is based on the number and distribution 
of intestinal segments with villous oedema, ulceration and steno-
sis. To calculate the LS, the small bowel is first divided into equal 
thirds (tertiles) according to the transit time of the capsule. For each 
tertile, a numeric subscore is calculated, considering the extent and 
distribution of oedema and the number, size and distribution of 
ulcers. The final score is the sum of the worst-affected tertile plus 
the stenosis score (single/multiple, ulcerated/not ulcerated, traversed/
not traversed by the capsule). The LS allows small bowel inflam-
matory activity to be classified into three grades: (1) normal or 
clinically insignificant mucosal inflammatory change (LS <135); 
(2) mild disease (135 ≤ LS < 790); and (3) moderate to severe dis-
ease (LS ≥790).11 The LS has shown better performance than other 
SBCE scores in describing small bowel inflammation, with a good 
correlation with biochemical parameters of inflammation, such as 
C-reactive protein (CRP) and faecal calprotectin.12,13 This score was 
recently validated with strong interobserver agreement,14 reinforcing 
its utility in reporting small bowel inflammatory activity in clinical 
practice.
Even though SBCE has an important role in the management of 
patients with CD,7,15 the prognostic value of inflammatory activity 
in the follow-up of these patients has not been assessed yet. If such 
inflammatory activity negatively impacts clinical outcome, it may 
influence therapeutic strategy and the management of patients with 
CD. In this setting we aimed to evaluate the prognostic value of the 
severity of inflammatory lesions at the time of diagnosis, quantified 
by the LS, in patients with isolated small bowel CD.
2. Methods
We performed a retrospective, single-centre study from January 2008 
to December 2013, including all consecutive patients undergoing 
SBCE for suspected CD or with known isolated non-stricturing and 
non-penetrating small bowel CD, to assess the entire small bowel at 
the time of diagnosis. In patients with established CD (diagnosed 
by ileocolonoscopy), SBCE was performed within 1 month after its 
diagnosis, and no immunosuppressive therapy (anti-tumour necro-
sis factor [anti-TNF] and/or thiopurines) was initiated in the period 
between diagnosis and SBCE. All patients had had an ileocolonoscopy 
as the first endoscopic diagnostic procedure. Patients with obstructive 
symptoms and/or those with evidence of ileal stenoses at ileocolonos-
copy and/or radiological or cross-sectional features of stricturing or 
penetrating disease were not eligible for SBCE and thus did not enter 
this study. Patients taking aspirin or non-steroidal anti-inflammatory 
drugs discontinued the medication at least 4 weeks before the SBCE 
examination, based on recommendations.16 Patients followed a clear 
liquid diet for 24 h and then fasted for 12 h prior to SBCE (PillCam® 
SB2, Medtronic®). The SBCE videos were reviewed and the LS was 
calculated using the software application in the RAPID Reader® v.6, 
v.7 or v.8 workstation. Using the software application to calculate 
the LS, the small bowel was automatically divided into equal thirds 
(tertiles) according to the transit time of the capsule; in those cases 
where the capsule did not reach the caecum, small bowel tertiles were 
determined based on the last small bowel image. Based on another 
study in this field,7 small bowel lesions were considered to have a 
proximal location if they were located in the upper two-thirds of the 
small bowel (first two tertiles of the SBCE) and had an LS ≥135. Small 
bowel inflammatory activity was classified into two grades: mild dis-
ease (135 ≤ LS < 790) and moderate to severe disease (LS ≥790).
All patients had at least 12 months of follow-up after diagnosis 
(mean 42 ± 17 months, range 12–77 months). The clinical variables 
evaluated at diagnosis were smoking status, family history of inflam-
matory bowel disease, extraintestinal manifestations, perianal dis-
ease, history of appendicectomy, treatment initiated after SBCE, and 
laboratory variables including serum haemoglobin, CRP, erythrocyte 
sedimentation rate (ESR) and ferritin.
The variables defined as adverse events,2 indicating a worse out-
come, were disease flare requiring systemic corticosteroid therapy, 
hospitalization and surgery during follow-up (excluding the presen-
tation episode). The incidence of adverse events was analysed and 
compared between patients with higher LS (LS ≥790), corresponding 
to moderate or severe inflammatory activity, and patients with mild 
inflammatory activity (LS between 135 and 790).
Statistical analysis was performed with Statistical Package for 
the Social Sciences (SPSS) software version 20.0 (IBM, Armonk, 
New York, USA). The baseline quantitative data are presented as 
mean ± SD. For nominal variables, the χ2 test or Fisher’s exact test 
was used as appropriate, and Student’s t-test was used for quan-
titative variables with normal distribution. Binary logistic regres-
sions were adjusted considering as independent variables smoking 
status, family history of inflammatory bowel disease, extraintestinal 
manifestations, perianal disease, history of appendicectomy, small 
bowel inflammatory activity, and laboratory variables (serum hae-
moglobin, CRP, ESR and ferritin). Laboratory variables were used 
as quantitative variables. The variables measured at diagnosis were 
included as predictors if they were selected from bivariate analy-
sis (p  <  0.1). Predictive performance of the model was tested by 
assessing its discrimination (correct classification) and calibration 
(whether probabilities predicted by the model matched observed 
probabilities). Discrimination was measured using the area under 
the receiver operating characteristic curve (AUROC), and 95% con-
fidence intervals (CIs) were reported.17 A p value of less than 0.05 
was considered statistically significant. All patients provided written 
informed consent for SBCE. The study was performed according to 
the Declaration of Helsinki and approved by the local ethics board 
of Centro Hospitalar do Alto Ave, Guimarães, Portugal.
3. Results
3.1. Patients’ characteristics
Fifty-three consecutive patients were included (mean age 
33 ± 13 years, 64% females), 57% underwent SBCE for suspected 
CD and 43% to assess disease extent and activity, at the time of diag-
nosis, in patients with known non-stricturing and non-penetrating 
ileal CD. Baseline characteristics are summarized in Table 1.
Small bowel imaging was performed in 24 patients (45%) prior 
to SBCE, revealing features of ileitis or unremarkable findings. 
Upper endoscopy was performed in 21 patients (40%), revealing no 
features of CD in any of the patients.
There were no statistical differences between the 2 groups (mild dis-
ease [135 ≤ LS < 790] vs moderate to severe disease [LS ≥790]), con-
sidering most of the clinical or laboratory variables studied (Table 1). 
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However, in the group of patients with moderate to severe disease the 
frequencies of smokers (36 vs 10%, p = 0.036) and male sex (55 vs 23%, 
p = 0.017) were higher. The mean follow-up after SBCE was 42 months 
(range 12–77 months), with no difference between the two groups.
3.2. SBCE findings
Overall, SBCE detected mild lesions (135 ≤ LS < 790) in 31 patients 
(58.5%) and moderate to severe (LS ≥ 790) in 22 patients (41.5%). 
Among the 53 patients included in the study, 36 (68%) had signifi-
cant inflammatory activity in the proximal small bowel; 10 of them 
had moderate to severe disease (LS ≥ 790). In 8 patients (15%) a 
stenosis was detected in SBCE, but capsule retention only occurred 
in 3 patients (6%). This occurred in 2 patients with suspected CD 
and in 1 patient with established CD who had no previous history 
of obstructive symptoms and had been submitted to small bowel 
cross-sectional imaging that did not identify any stenosis. The first 2 
patients with suspected CD underwent surgery to retrieve the cap-
sule and to confirm the diagnosis after an unsuccessful attempt at 
endoscopic removal. The patient with established CD was managed 
medically. The frequency of complete examinations, with the capsule 
reaching the caecum within the battery life, was 77% (n = 41).
3.3. Follow-up after SBCE
During the follow-up period, 25 patients (47%) experienced at least 
one disease flare, leading to surgery, hospitalization or corticoster-
oid therapy. In general, several risk factors for a disease flare were 
identified as relevant by univariate analysis: the presence of moder-
ate to severe inflammatory activity (p < 0.001), the presence of peria-
nal disease (p = 0.067) and higher levels of ESR and CRP (p = 0.095 
and p = 0.019, respectively) Table 2. However in a binary logistic 
regression analysis considering these variables, only the presence 
of moderate to severe inflammation and perianal disease remained 
independent risk factors for disease flare, with a relative risk (RR) 
of 12.7 (p = 0.002; 95% CI 2.6–61.8) and 10.6 (p = 0.024; 95% 
CI 1.4–82.1), respectively (Table 3). The predictive performance of 
these variables for a disease flare was excellent, with an AUROC of 
0.86 (95% CI 0.746–0.975).
Binary logistic regression models were also adjusted for each 
adverse event separately (surgery, hospitalization and corticosteroid 
therapy). None of the variables were associated with a higher risk 
for surgery. By univariate analysis smoking (p = 0 .09) and moderate 
to severe disease at SBCE (p = 0 .003) were statistically associated 
with a higher risk of corticosteroid therapy. However, in multivariate 
analysis only moderate to severe disease at SBCE was independently 
associated with corticosteroid therapy during follow-up, with an RR 
of 5 (p = 0.011; 95% CI 1.5–17.8). Moderate to severe disease at 
SBCE (p = 0 .006) and mean haemoglobin levels (11.9 vs 13.8 g/
dL; p = 0.001) at diagnosis were associated with hospitalization in 
univariate analysis and were also independent risk factors for hos-
pitalization in multivariate analysis, with an RR of 13.7 (p = 0.028; 
95% CI 1.3–141.9) and 0.3/unit (p  =  0.028; 95% CI 0.1–0.9), 
respectively.





Mild disease  
(135 ≤ LS <790)




 Male 7 (23%) 12 (52%) 7 (23%) 12 (55%)
 Female 23 (77%) 11 (48%) 24 (77%) 10 (45%)
Age at SBCE, mean (SD), y 36 ± 15 29 ± 11 34 ± 11 32 ± 16 0.579
Follow-up after SBCE, mean 
(SD), mo
45 ± 17 39 ± 18 42 ± 18 43 ± 18 0.825
Smoker 0.036
 Yes 5 (17%) 6 (26%) 3 (10%) 8 (36%)
 No 25 (83%) 17 (74%) 28 (90%) 14 (64%)
Family history of IBD 1.000
 Yes 4 (13%) 2 (9%) 4 (13%) 2 (9%)
 No 26 (87%) 21 (91%) 27 (87%) 20 (91%)
Perianal disease 0.720
 Yes 4 (13%) 5 (22%) 6 (19%) 3 (14%)
 No 26 (87%) 18 (78%) 25 (81%) 19 (86%)
Extraintestinal manifestations 0.382
 Yes 5 (17%) 1 (4%) 5 (16%) 1 (5%)
 No 25 (83%) 22 (96%) 26 (84%) 21 (95%)
History of appendectomy 0.295
 Yes 4 (13%) 0 (0%) 1 (3%) 3 (14%)
 No 26 (87%) 23 (100%) 30 (97%) 19 (86%)
Haemoglobin, mean (SD), g/dL 13.5 ± 1.9 13.5 ± 1.1 13.7 ± 1.4 13.2 ± 1.8 0.349
CRP, mean (SD), mg/dL 11.7 ± 25.1 22.5 ± 31.2 10.8 ± 24.7 24.0 ± 31.4 0.086
ESR, mean (SD), mm/h 19.0 ± 15.4 20.1 ± 16.6 18.4 ± 15.2 21,1 ± 16.9 0.554
Ferritin, mean (SD), mg/dL 74.7 ± 61.6 78.0 ± 88.6 70.8 ± 55.1 83.9 ± 95.4 0.535
Lewis score, mean (SD) 1 077 ± 1 519 1 796 ± 1 589 338 ± 169 2 871 ± 1 476
Proximal small bowel lesions 18 (60%) 18 (78%) 19 (61%) 17 (77%) 0.219
Thiopurines and/or anti-TNF 0.004
 Yes 11 (37%) 15 (65%) 10 (32%) 16 (73%)
 No 19 (63%) 8 (35%) 21 (68%) 6 (27%)
CD, Crohn’s disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LS, Lewis score; SBCE, small bowel capsule endoscopy; TNF, tumour ne-
crosis factor.
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After SBCE, 16 patients in the moderate to severe group started 
immunosuppressive therapy (azathioprine or azathioprine and/or anti-
TNF therapy) vs 10 patients in the mild group (73 vs 32%, p = 0.004). 
However, even with more effective therapy the group of patients with 
moderate to severe disease at SBCE presented with higher frequen-
cies of surgery (p = 0.071), hospitalizations (p = 0.006) and new flares 
requiring corticosteroid therapy (p = 0.003) during follow-up (Table 2).
The proportion of patients that started treatment with thiopu-
rines and/or biologics after SBCE was higher among patients with 
proximal small bowel lesions (p  =  0.011). However, the numbers 
of surgeries, hospitalizations and corticosteroid therapies during 
follow-up were not different between patients with and without 
proximal small bowel lesions.
4. Discussion
The impact of the severity of endoscopic inflammation, quantified 
by the LS, in defining an aggressive course in patients with isolated 
small bowel CD has been scarcely reported in the literature thus 
far. In this study we assessed the prognostic value of the severity of 
inflammatory lesions, quantified by the LS, in patients with isolated 
small bowel CD, concluding that in patients with moderate to severe 
inflammatory activity (LS ≥790) at SBCE the prevalence of disease 
flares leading to corticosteroid therapy demand and hospitalizations 
during follow-up was higher when compared with patients with 
mild inflammatory activity (135 ≤ LS < 790).
The ECCO guidelines are clear about the importance of assess-
ing the location and extent of CD in the small bowel at diagnosis, 
in order to establish the prognosis and to better define the thera-
peutic strategy.2 Rosa et  al.18 demonstrated the importance of the 
LS to characterize and grade the inflammatory activity on SBCE in 
providing an earlier and more accurate diagnosis of CD in patients 
with suspected inflammatory bowel disease (IBD). A meta-analysis19 
compared the diagnostic yield of SBCE with other imaging modali-
ties in patients with CD, including push enteroscopy, small bowel 
follow-through and CTE showed an overall superiority of SBCE 
over other imaging techniques. Although cross-sectional imaging has 
the advantage of evaluating the deep layers of the bowel wall and 
enabling the assessment of extra-luminal involvement, they have sev-
eral limitations when compared with SBCE, such as lower sensitivity, 
heterogeneous availability and feasibility among different medical 
centres, variable observer expertise, claustrophobia for MRE, radia-
tion exposure and contrast sensitivity for CTE.
Several studies20–23 have tried to define clinical predictors of disa-
bling and/or severe CD at diagnosis to clarify which patients should 
be considered for early treatment with thiopurines and/or biologics. 
The study of Beaugerie et al.20 showed that perianal lesions, younger 
age and ileocolonic disease were associated with a poor prognosis in 
CD. In association with clinical factors, endoscopic scoring systems 
have shown prognostic relevance in patients with ileocolonic disease 
and the ability to predict postoperative recurrence.4
In recent studies6,7 the prevalence of jejunal lesions in patients 
with CD was up to 50%. In concordance, in our study proximal 
significant inflammatory activity was detected in 68% of patients, 
which is indeed a very high prevalence of lesions out of reach of the 
colonoscope, often missed by other conventional imaging modalities. 
As in the study by Flamant et al.,6 we found an association between 
proximal lesions and the start of therapy that included immunosup-
pressant and/or biologic agents shortly after SBCE; however, in our 
cohort this subset of patients did not have a higher prevalence of 
disease flares during follow-up.
In our study, the LS was determined to objectively quantify 
inflammatory activity and was associated with the likelihood of 
starting immunomodulators, as shown in a recent study.7 In addition 
to these findings, on multivariate analysis only moderate to severe 
inflammatory activity at SBCE could predict independently any type 
of disease flare and, when analysed separately, the need for corti-
costeroid therapy and hospitalization, which is in concordance with 
previous studies performed in patients with ileocolonic CD.24
An LS ≥790 at presentation was associated with a trend to intes-
tinal resection during follow-up, but this association was not statis-
tically significant in either univariate or multivariate analysis. This 
may be related to the fact that only 6 patients underwent surgery (3 
for occlusive symptoms and 3 for penetrating disease developed dur-
ing follow-up), and for that reason we cannot exclude the possibility 
Table 3. Binary logistic regression for disease flare.
Predictor RR 95% CI p value R2 (Nagelkerke)
Lewis score ≥790 12.7 2.6 – 61.8 0.002 0.51
Perianal disease 10.6 1.4 – 82.1 0.024
C-reactive protein 1.0 0.9 – 1.1 0.205
Erythrocyte sedi-
mentation rate
1.0 0.9 – 1.1 0.747
AUROC p value 95% CI
0.86 <0.001 0.746–0.975
RR, relative risk; CI, confidence interval.
Table 2. Univariate analysis of characteristics predictors of relapses.
Relapse No relapse p value
Gender 0.983
 Male 9 (36%) 10 (36%)
 Female 16 (64%) 18 (64%)
Age at SBCE, mean (SD), y 32 ± 15 33 ± 11 0.745
Smoker 0.219
 Yes 7 (28%) 4 (14%)
 No 18 (72%) 24 (86%)
Family history of  
inflammatory bowel disease
0.196
 Yes 1 (4%) 5 (18%)
 No 24 (96%) 23 (82%)
Perianal disease 0.067
 Yes 7 (28%) 2 (7%)
 No 18 (72%) 26 (93%)
Extraintestinal manifestations 0.404
 Yes 4 (16%) 2 (7%)
 No 21 (84%) 26 (93%)
History of appendectomy 0.333
 Yes 3 (12%) 1 (4%)
 No 22 (88%) 27 (96%)
Lewis score ≥790 17 (68%) 5 (18%) 0.001
Lewis score 2191 ± 1801 674 ± 880 0.001
Proximal small bowel lesions 18 (72%) 18 (64%) 0.548
Haemoglobin,  
mean (SD), g/dL
13.2 ± 1.9 13.7 ± 1.3 0.254
C-reactive protein,  
mean (SD), mg/dL
26.5 ± 37.8 7.2 ± 8.6 0.019
Erythrocyte sedimentation 
rate, mean (SD), mm/h
23.5 ± 15.9 16.1 ± 15.2 0.095
Ferritin, mean (SD), mg/dL 65.3 ± 56.1 85.3 ± 85.5 0.333
SBCE, small bowel capsule endoscopy.
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of a type II error. The lower incidence of surgery during follow-up 
in our study probably resulted from selection bias of patients with 
non-stricturing and non-penetrating small-bowel CD.
According to the current trend, the treatment goal for CD is to 
achieve mucosal healing, which has been shown to increase corticos-
teroid-free remission and decrease surgery rates.25,26 A  recent pro-
spective study tried to assess small bowel mucosal healing in CD 
patients 52 weeks after initiating immunomodulators and biologic 
therapy.27 The authors demonstrated a rate of complete mucosal 
healing that was similar (up to 50%) to that seen in previous stud-
ies of ileocolonic CD.28 However, in patients with a stricture identi-
fied on SBCE the outcome was poor, these patients having a higher 
chance of requiring surgery during follow-up. Importantly, this study 
has shown that SBCE is capable of safely and accurately monitoring 
the treatment response in patients with small bowel CD; we believe 
that the application of an index score is the only way to assess 
mucosal healing and treatment response in CD.
To our knowledge, this is the first study to assess the importance 
of SBCE and the LS in the definition of CD patients’ outcomes. 
Our results support the idea that the grade of inflammatory activ-
ity (LS ≥790) is a more powerful predictor of worse prognosis than 
the lesion location itself. However, prospective studies are needed 
to confirm these data. In future it will be fundamental to identify 
patients with poor prognosis and risk of disabling disease at diagno-
sis, as they may benefit from more intensive treatments.
Our study has some limitations related to the heterogeneity of 
the patients and the retrospective design of the study. This is impor-
tant since clinical decisions regarding the outcomes evaluated in this 
study (surgery, hospitalization and corticosteroid therapy) are often 
complex, multifactorial and multidisciplinary, and certainly do not 
rely on a single feature. However, in our centre we attempted to 
lessen this limitation, consolidating these decisions in 1 gastroenter-
ologist, together with 1 surgeon (in case of surgery) fully dedicated 
to IBD. Additionally, patients with higher LS had worse prognosis 
even though they had received immunosuppressive therapy (anti-
TNF and/or thiopurines) more frequently. In fact, there is a potential 
bias of higher LS indirectly reducing the incidence of negative out-
comes by leading to a more aggressive therapeutic management, and 
in our study this may have resulted in underestimation of an even 
more pronounced effect of the LS regarding worse prognosis.
Another limitation is the relatively low SBCE completion rate 
(77%), with the potential to underestimate the LS. The completion 
rate in our study was similar to others reported for patients with 
established CD;29 this prolonged transit time might be explained by 
delay in capsule progression in segments with inflammatory activity 
such as oedema and strictures, and possibly by alteration in the gut’s 
motility.7,30
Regarding capsule retention, even though the rate of retention 
was low (4% in patients with established CD) compared with data 
reported in the literature,25 in patients with established CD the con-
tribution of disease extent evaluation may be a matter of discussion, 
whereas capsule retention can lead to invasive procedures or to sur-
gery. In our study, only 1 patient with established CD presented with 
obstructive symptoms but was managed successfully with medical 
treatment. As a matter of fact, a recent study presented at Digestive 
Disease Week 201531 concluded that capsule retention is a rare event 
in patients with established CD, and the risk of capsule retention was 
not decreased by routine use of a patency capsule in all CD patients. 
However, SBCE in CD patients after positive capsule patency is asso-
ciated with a high risk of capsule retention, and thus it may be useful 
in selected at-risk populations.
To conclude, the role of SBCE in the management and outcome 
of patients with small bowel CD is still evolving. Although further 
prospective studies are required, our study reinforces the importance 
of the LS in the management and prognosis of patients with small 
bowel CD, proving that higher inflammatory activity at diagnosis is 
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